Bioresorbable Scaffolds for Coronary Artery Disease.
Curr Cardiol Rep
; 19(1): 5, 2017 01.
Article
en En
| MEDLINE
| ID: mdl-28108898
ABSTRACT
PURPOSE OF REVIEW The purpose of this review is to present an overview of the recent evidence regarding the use of bioresorbable scaffolds in percutaneous coronary intervention. RECENT FINDINGS:
Bioresorbable scaffolds represent a potentially unique engineering solution to the problems associated with metallic stents. The Absorb everolimus-eluting bioresorbable scaffold has been the most extensively tested of this class and is currently Food and Drug Administration-approved for use in the USA. While early studies suggested that it has comparable overall efficacy as compared to drug-eluting metallic stents, they also demonstrated a significantly increased risk of stent thrombosis. Bioresorbable scaffolds may be comparable to drug-eluting stents, though associated with an increased risk of stent thrombosis. They are a nascent technology with several competitive product designs in development and continued iterative technological improvements are expected over the next several years.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de la Arteria Coronaria
/
Angioplastia Coronaria con Balón
/
Implantes Absorbibles
/
Andamios del Tejido
/
Everolimus
/
Inmunosupresores
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Curr Cardiol Rep
Asunto de la revista:
CARDIOLOGIA
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos